Bedinvetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Librela |
| AHFS/Drugs.com | Veterinary Use |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
Bedinvetmab, sold under the brand name Librela, is a fully canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.[3][4][5] Librela is sponsored by Zoetis.[5][6]
Bedinvetmab was approved for medical use in the European Union in November 2020,[4] and in the United States in May 2023.[5][6] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.[5]
- ^ "Librela Product information". Health Canada.
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ a b "Librela (bedinvetmab injection) Injectable Solution Dogs". Zoetis Inc. U.S. Food and Drug Administration. NADA 141-562.
- ^ a b c "Librela EPAR". European Medicines Agency (EMA). 21 February 2022. Archived from the original on 16 March 2023. Retrieved 13 May 2023.
- ^ a b c d "FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain". U.S. Food and Drug Administration (FDA). 5 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
- ^ a b "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.